Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Pancreatic Adenocarcinoma 1

Interventions

Cisplatin 726Carboplatin 609Paclitaxel 579Cyclophosphamide 516Radiotherapy 511Docetaxel 477Fluorouracil 454Gemcitabine 438Doxorubicin 383Capecitabine 362Dexamethasone 328Oxaliplatin 289pembrolizumab 283Leucovorin 283Bevacizumab 275Etoposide 272Vincristine 270Rituximab 246Prednisone 223Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 176Irinotecan 174Methotrexate 171Lenalidomide 137Nivolumab 136Filgrastim 135Epirubicin 129Tamoxifen 128

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × beta-D-glucosylisophosphoramide mustard × Clear all
NCT01954992 2024-12-31

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Eleison Pharmaceuticals LLC.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT00099294 2009-04-30

Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic Cancer

Threshold Pharmaceuticals

Phase 3 Completed
300 enrolled
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡